Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
There is a growing epidemic of the bacterial sexually transmitted infections (STIs) syphilis,
chlamydia and gonorrhea worldwide; similarly concerning trends have been noted in Canada,
where increases of over 160% have been seen in bacterial STIs over the last decade. In
Canada, gay, bisexual, and other men who have sex with men (gbMSM) - including those living
with HIV - are disproportionately impacted by bacterial STIs5,6These dramatic increases in
bacterial STIs, the potential development of serious complications including AMR, and waning
effectiveness of the promotion of conventional STI prevention tools (e.g. condoms), signals
the need for novel STI prevention strategies and tools to mitigate STI-related complications.
A rigorous randomized controlled trial will be conducted to definitively assess the efficacy,
safety, antimicrobial resistance profiles and costs associated with doxycycline-based STI
prevention